NCT00274638已完成4 期
A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group 6-week Treatment Study Comparing Telmisartan Combined With Hydrochlorothiazide (40 mg/12.5 mg or 80 mg/12.5 mg) Tablets With Losartan Combined With Hydrochlorothiazide (50 mg/12.5 mg) Tablets Using Ambulatory Blood Pressure Monitoring in Patients With Mild-to-Moderate Hypertension
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 805
- 试验地点
- 74
- 主要终点
- Change from baseline in the last 6-hour mean (relative to dose time) diastolic blood pressure (DBP) as measured by ABPM (Ambulatory Blood Pressure Monitoring)
研究概览
简要总结
To demonstrate that Telmisartan combined with Hydrochlorothiazide (MICARDIS® HCT) is superior to Losartan with Hydrochlorothiazide (Hyzaar®) in lowering blood pressure in mild-moderate hypertensives.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to provide written informed consent in accordance with GCP and local legislation.
- •Mild-to-moderate hypertension defined as a mean seated DBP of >= 95 mm Hg and <=l to 109 mm Hg, measured by manual cuff sphygmomanometer at Visit
- •Male or Female >= 18 years.
- •Ability to stop any current antihypertensive therapy without risk to the patient (investigator's discretion).
- •24-hour ABPM mean DBP of >= 85 mm Hg at Visit 3.
排除标准
- •Pre-menopausal women (last menstruation <= 1 year prior to signing informed consent) who
- •are not surgically sterile, or are
- •nursing, or
- •are of child-bearing potential and are NOT practicing acceptable methods of birth control, or do not plan to continue practicing an acceptable method throughout the study. Acceptable methods of birth control include IUD, oral, implantable or injectable contraceptives. No exception will be made.
- •Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 A.M.
- •Mean seated SBP >= 180 mm Hg or mean seated DBP >= 110 mm Hg during any visit or the placebo run-in phase.
- •Known or suspected secondary hypertension (i.e. pheochromocytoma).
- •Hepatic and/or renal dysfunction as defined by the following laboratory parameters: a)SGPT (ALT) or (SGOT) AST less than two times the upper limit of normal range, or b)Serum creatinine greater than 2.3 mg/dL (>203 mico mol/l).
- •Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney.
- •Biliary obstructive disorders.
- •Clinically relevant sodium depletion, hypokalaemia or hyperkalaemia.
- •Uncorrected volume depletion.
- •Primary aldosteronism.
- •Hereditary fructose intolerance.
- •Congestive heart failure (NYHA functional class CHF III-IV).
- •Unstable angina within the past 3 months prior to signing the informed consent form.
- •Stroke within the past 6 months prior to signing the informed consent form.
- •Myocardial infarction or cardiac surgery within the past 3 months prior to signing the inform consent form.
- •PTCA (percutaneous transluminal coronary angioplasty) within the past 3 months prior to signing the informed consent form.
- •Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator.
- •Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve.
- •Patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past 3 months as defined by an HbA1C >= 10 Percent.
- •Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists.
- •History of drug or alcohol dependency within 6 months prior to signing the informed consent form.
- •Chronic administration of any medications known to affect blood pressure, except medication allowed by the protocol.
- •Any investigational therapy within 1 month of signing the informed consent form.
- •Known hypersensitivity to any component of the study drugs (placebo, telmisartan, hydrochlorothiazide or losartan).
- •Any clinical condition which, in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication.
- •Concomitant use of lithium or cholestyramine or colestipol resins (potential drug interactions with hydrochlorothiazide).
- •History of non-compliance with prescribed medication.
- •Inability to comply with protocol.
结局指标
主要结局
Change from baseline in the last 6-hour mean (relative to dose time) diastolic blood pressure (DBP) as measured by ABPM (Ambulatory Blood Pressure Monitoring)
时间窗: after 6 Weeks
次要结局
- Responder rates based on both the 24-hour ABPM mean (relative to dose time) blood pressures and the in-clinic trough cuff measurements(after 6 weeks)
- Change in the last 6-hour ABPM mean (relative to dosing time) for systolic blood pressure (SBP)(after 6 weeks)
- Change in systolic and diastolic blood pressure load during the 24-hour dosing interval of the 24-hour dosing interval(after 6 weeks)
- Change in the ABPM mean DBP and SBP during the morning, daytime, and night-time periods of the 24-hour dosing interval(after 6 weeks)
- Change in mean seated trough DBP and SBP as measured by manual in-clinic cuff sphygmomanometer(after 6 weeks)
- Change in the 24-hour ABPM mean (relative to dosing time) for DBP and SBP(after 6 weeks)
研究者
研究点 (74)
Loading locations...
相似试验
已完成
2 期
3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential HypertensionHypertensionNCT00153049Boehringer Ingelheim583
已完成
4 期
SMOOTH - Blood Pressure Control in Diabetic/Obese PatientsHypertensionDiabetes Mellitus, Type 2NCT00239538Boehringer Ingelheim840
已完成
3 期
Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate HypertensionHypertensionNCT02177435Boehringer Ingelheim491
已完成
不适用
Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake PopulationHypertensionNCT02255253The George Institute for Global Health, China1,410
已完成
4 期
Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPMHypertensionNCT00274612Boehringer Ingelheim801